Recent Advances in Retinoblastoma Treatment

Francis, Jasmine H.; Abramson, David H.

doi:10.1007/978-3-319-19467-7

Cited by 5 publications

(2 citation statements)

References 179 publications

(268 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite having experience for more than 30 years with over 400 eyes, the technique was only performed in Japan. The modern era for OAC began following establishment of the technique by Abramson and Gobin at MSK in 2006 (15,33). Since then, it has been adopted as primary and salvage therapy for both unilateral and bilateral retinoblastoma worldwide and is performed in more than 45 countries.…”

Section: Ophthalmic Artery Chemosurgerymentioning

confidence: 99%

“…Since then, it has been adopted as primary and salvage therapy for both unilateral and bilateral retinoblastoma worldwide and is performed in more than 45 countries. Every series published to date, from the US, China, India, Argentina, Italy, Switzerland, Malaysia, and others, has concluded that the technique is better, safer, and more effective (33)(34)(35)(36)(37)(38)(39).…”

Section: Ophthalmic Artery Chemosurgerymentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Retinoblastoma: What Is the Latest and What Is the Future

et al. 2022

View full text Add to dashboard Cite

The management of retinoblastoma, the most common intraocular malignancy in children, has changed drastically over the last decade. Landmark developments in local drug delivery, namely, safer techniques for intravitreal chemotherapy injection and ophthalmic artery chemosurgery, have resulted in eye globe salvages that were not previously attainable using systemic chemotherapy or external beam irradiation. Novel drugs, oncolytic viruses, and immunotherapy are promising approaches in the treatment of intraocular retinoblastoma. Importantly, emerging studies of the pattern of tumor dissemination and local drug delivery may provide the first steps toward new treatments for metastatic disease. Here, we review recent advances in retinoblastoma treatment, especially with regard to local drug delivery, that have enabled successful conservative management of intraocular retinoblastoma. We also review emerging data from preclinical and clinical studies on innovative approaches that promise to lead to further improvement in outcomes, namely, the mechanisms and potential uses of new and repurposed drugs and non-chemotherapy treatments, and discuss future directions for therapeutic development.

show abstract

Section: Ophthalmic Artery Chemosurgerymentioning

confidence: 99%

Section: Ophthalmic Artery Chemosurgerymentioning

confidence: 99%

Treatment of Retinoblastoma: What Is the Latest and What Is the Future

et al. 2022

View full text Add to dashboard Cite

show abstract

A bilayer photoreceptor-retinal tissue model with gradient cell density design: A study of microvalve-based bioprinting

Shi

Tan

Yeong

et al. 2018

J Tissue Eng Regen Med

View full text Add to dashboard Cite

ARPE-19 and Y79 cells were precisely and effectively delivered to form an in vitro retinal tissue model via 3D cell bioprinting technology. The samples were characterized by cell viability assay, haematoxylin and eosin and immunofluorescent staining, scanning electrical microscopy and confocal microscopy, and so forth. The bioprinted ARPE-19 cells formed a high-quality cell monolayer in 14 days. Manually seeded ARPE-19 cells were poorly controlled during and after cell seeding, and they aggregated to form uneven cell layer. The Y79 cells were subsequently bioprinted on the ARPE-19 cell monolayer to form 2 distinctive patterns. The microvalve-based bioprinting is efficient and accurate to build the in vitro tissue models with the potential to provide similar pathological responses and mechanism to human diseases, to mimic the phenotypic endpoints that are comparable with clinical studies, and to provide a realistic prediction of clinical efficacy.

show abstract